




RealRate

PHARMACEUTICAL 2014

Tetraphase Pharmaceuticals INC
Rank 118 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Tetraphase Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tetraphase Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 112% points. The greatest weakness of Tetraphase Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is 259%, being 17% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	105,420
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,191
Liabilities, Non-Current	0
Other Assets	231
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-6,906
Other Revenues	18,271
Property and Equipment	235
Research and Development	106,615
Selling, General and Administrative Expense	24,471

Output Variable	Value in 1000 USD
Assets	105,886
Liabilities	13,191
Expenses	131,086
Revenues	18,271
Stockholders Equity	92,695
Net Income	-119,721
Comprehensive Net Income	-119,721
BaseVar	137,670
ECR before LimitedLiability	138%
Economic Capital Ratio	259%